Recapitulating And Correcting Marfan Syndrome In A Cellular Model
Jung Woo Park,Li Yan,Chris Stoddard,Xiaofang Wang,Zhichao Yue,Leann Crandall,Tiwanna Robinson,Yuxiao Chang,Kyle Denton,Enqin Li,Bin Jiang,Zhenwu Zhang,Kristen Martins-Taylor,Siu-Pok Yee,Hong Nie,Feng Gu,Wei Si,Ting Xie,Lixia Yue,Ren-He Xu
DOI: https://doi.org/10.7150/ijbs.19517
2017-01-01
International Journal of Biological Sciences
Abstract:Marfan syndrome (MFS) is a connective tissue disorder caused by mutations in FBN1 gene, which encodes a key extracellular matrix protein FIBRILLIN-1. The haplosufficiency of FBN1 has been implicated in pathogenesis of MFS with manifestations primarily in cardiovascular, muscular, and ocular tissues. Due to limitations in animal models to study the late-onset diseases, human pluripotent stem cells (PSCs) offer a homogeneic tool for dissection of cellular and molecular pathogenic mechanism for MFS in vitro. Here, we first derived induced PSCs (iPSCs) from a MFS patient with a FBN1 mutation and corrected the mutation, thereby generating an isogenic "gain-of-function" control cells for the parental MFS iPSCs. Reversely, we knocked out FBN1 in both alleles in a wild-type (WT) human embryonic stem cell (ESC) line, which served as a loss-of-function model for MFS with the WT cells as an isogenic control. Mesenchymal stem cells derived from both FBN1-mutant iPSCs and -ESCs demonstrated reduced osteogenic differentiation and microfibril formation. We further demonstrated that vascular smooth muscle cells derived from FBN1-mutant iPSCs showed less sensitivity to carbachol as demonstrated by contractility and Ca2+ influx assay, compared to the isogenic controls cells. These findings were further supported by transcriptomic anaylsis of the cells. Therefore, this study based on both gain-and loss-of-function approaches confirmed the pathogenetic role of FBN1 mutations in these MFS-related phenotypic changes.